LGND Q4 2023 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M+3.9% YoY

Gross Profit

$26M94.1% margin

Operating Income

-$3M-11.9% margin

Net Income

$18M64.7% margin

EPS (Diluted)

$1.03

QoQ Revenue Growth

-14.5%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$7M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$787M

Total Liabilities

$86M

Stockholders' Equity

$701M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$27M	+3.9%
Gross Profit	$26M	$5M	+386.8%
Operating Income	-$3M	$12M	-127.6%
Net Income	$18M	-$17M	+204.0%

Revenue Segments

Royalty

$22M60%

Material Sales, Captisol, Core

$4M10%

Material Sales, Captisol

$4M10%

Royalty, Other

$4M9%

Contract Revenue

$2M5%

Milestone

$2M4%

Service

$352,0001%